Ottavio Arancio

List of Publications by Year
in descending order

173	22,219	10351 72	8835 145
papers	citations	h-index	g-index

190	190	190	25203
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Extracellular tau oligomers affect extracellular glutamate handling by astrocytes through downregulation of GLTâ€1 expression and impairment of NKA1A2 function. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	7
2	Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimerâ€™s disease. Brain, 2022, 145, 2849-2868.	3.7	32
3	Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice. Journal of Alzheimer's Disease, 2021, 79, 1813-1829.	1.2	4
4	Genetic deletion of Î±7 nicotinic acetylcholine receptors induces an age-dependent Alzheimerâ€™s disease-like pathology. Progress in Neurobiology, 2021, 206, 102154.	2.8	21
5	The penalty of stress â€•Epichaperomes negatively reshaping the brain in neurodegenerative disorders. Journal of Neurochemistry, 2021, 159, 958-979.	2.1	14
6	Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas. Blood, 2021, 138, 2254-2254.	0.6	0
7	What Does the APP Family Do in the Brain?. Neuron, 2020, 108, 583-585.	3.8	6
8	Involvement of p38 MAPK in Synaptic Function and Dysfunction. International Journal of Molecular Sciences, 2020, 21, 5624.	1.8	96
9	Stem Cell Therapy for Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1266, 39-55.	0.8	30
10	Reduced Expression of the PP2A Methylesterase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice. Journal of Neuroscience, 2020, 40, 4596-4608.	1.7	4
11	Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimerâ€™s disease. Biochemical Pharmacology, 2020, 176, 113818.	2.0	52
12	Tau is not necessary for amyloid-Î²â€“induced synaptic and memory impairments. Journal of Clinical Investigation, 2020, 130, 4831-4844.	3.9	34
13	Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. Molecular Neurodegeneration, 2019, 14, 26.	4.4	59
14	Efficient Expression of HIV in Immunocompetent Mouse Brain Reveals a Novel Nonneurotoxic Viral Function in Hippocampal Synaptodendritic Injury and Memory Impairment. MBio, 2019, 10, .	1.8	26
15	Targeting the NO/cGMP/CREB Phosphorylation Signaling Pathway in Alzheimerâ€™s Disease. , 2019, , .		1
16	Neuromodulatory Action of Picomolar Extracellular Aî²42 Oligomers on Presynaptic and Postsynaptic Mechanisms Underlying Synaptic Function and Memory. Journal of Neuroscience, 2019, 39, 5986-6000.	1.7	71
17	A Selective and Brain Penetrant p38Î±MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction. Journal of Medicinal Chemistry, 2019, 62, 5298-5311.	2.9	31
18	Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy, 2019, 15, 113-130.	4.3	155

#	Article	IF	Citations
19	Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimerâ€™s models. Nature Medicine, 2019, 25, 165-175.	15.2	511
20	Involvement of SUMO1 in Alzheimer's disease pathology. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, 1-P-042.	0.0	0
21	Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators. Blood, 2019, 134, 4068-4068.	0.6	3
22	Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice. Annals of Clinical and Translational Neurology, 2018, 5, 240-251.	1.7	19
23	A role for tau in learning, memory and synaptic plasticity. Scientific Reports, 2018, 8, 3184.	1.6	95
24	Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 37-45.	1.8	29
25	RAGE mediates AÎ² accumulation in a mouse model of Alzheimerâ€™s disease via modulation of Î²- and Î³-secretase activity. Human Molecular Genetics, 2018, 27, 1002-1014.	1.4	62
26	SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model. Neurobiology of Disease, 2018, 110, 154-165.	2.1	21
27	An isoform-selective p38Î± mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 70, 86-91.	1.5	19
28	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. PLoS Pathogens, 2018, 14, e1007061.	2.1	51
29	The effect of amyloid-Î² peptide on synaptic plasticity and memory is influenced by different isoforms, concentrations, and aggregation status. Neurobiology of Aging, 2018, 71, 51-60.	1.5	55
30	Role of Amyloid-Î² and Tau Proteins in Alzheimerâ€™s Disease: Confuting the Amyloid Cascade. Journal of Alzheimer's Disease, 2018, 64, S611-S631.	1.2	102
31	Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease. Neuropharmacology, 2018, 138, 151-159.	2.0	27
32	Preparation of Tau Oligomers After the Protein Extraction from Bacteria and Brain Cortices. Methods in Molecular Biology, 2018, 1779, 85-97.	0.4	2
33	Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma. Blood, 2018, 132, 37-37.	0.6	2
34	Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 46320.	1.6	63
35	Amyloid-Î² Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory. Journal of Neuroscience, 2017, 37, 6926-6937.	1.7	59
36	Reduced gliotransmitter release from astrocytes mediates tauâ€induced synaptic dysfunction in cultured hippocampal neurons. Glia, 2017, 65, 1302-1316.	2.5	82

#	Article	IF	Citations
37	Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimerâ€™s disease-like pathologies and cognitive deficits. Acta Neuropathologica, 2017, 134, 749-767.	3.9	130
38	Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2017, 60, 8858-8875.	2.9	47
39	Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice. Journal of Alzheimer's Disease, 2017, 59, 743-751.	1.2	16
40	Commentary: Analysis of SUMO1-conjugation at synapses. Frontiers in Cellular Neuroscience, 2017, 11, 345.	1.8	19
41	Mitophagy Failure in Fibroblasts and iPSC-Derived Neurons of Alzheimerâ€™s Disease-Associated Presenilin 1 Mutation. Frontiers in Molecular Neuroscience, 2017, 10, 291.	1.4	86
42	CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimerâ€™s PSEN2 N141I neurons. Acta Neuropathologica Communications, 2017, 5, 77.	2.4	102
43	LTP and memory impairment caused by extracellular AÎ² and Tau oligomers is APP-dependent. ELife, 2017, 6, .	2.8	121
44	Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides. Frontiers in Aging Neuroscience, 2017, 9, 435.	1.7	29
45	Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimerâ€™s disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. PLoS ONE, 2017, 12, e0189413.	1.1	10
46	PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. Journal of Alzheimer's Disease, 2016, 52, 295-302.	1.2	40
47	Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric AÎ²42: an early index of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 32553.	1.6	54
48	New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment. European Journal of Medicinal Chemistry, 2016, 124, 82-102.	2.6	31
49	Betaâ€amyloid 1â€42 monomers, but not oligomers, produce <scp>PHF</scp> â€like conformation of Tau protein. Aging Cell, 2016, 15, 914-923.	3.0	27
50	A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 35.	4.4	27
51	Molecular Mechanisms of Learning and Memory**The authors declare no competing financial interests.. , 2016, , 1-27.		7
52	PP2A methylation controls sensitivity and resistance to Î²-amyloidâ€“induced cognitive and electrophysiological impairments. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3347-3352.	3.3	48
53	Time Course and Size of Bloodâ€“Brain Barrier Opening in a Mouse Model of Blast-Induced Traumatic Brain Injury. Journal of Neurotrauma, 2016, 33, 1202-1211.	1.7	49
54	SUMO1 Affects Synaptic Function, Spine Density and Memory. Scientific Reports, 2015, 5, 10730.	1.6	61

#	Article	IF	Citations
55	Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 49, 707-721.	1.2	24
56	Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia. BMC Neuroscience, 2015, 16, 67.	0.8	12
57	Network compensation of cyclic GMP-dependent protein kinase II knockout in the hippocampus by Ca ²⁺ -permeable AMPA receptors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3122-3127.	3.3	39
58	Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38Î±MAPK Inhibitor That Attenuates Disease Progression in Alzheimerâ€™s Disease Mouse Models. ACS Chemical Neuroscience, 2015, 6, 666-680.	1.7	75
59	Synaptic Therapy in Alzheimer's Disease: A CREB-centric Approach. Neurotherapeutics, 2015, 12, 29-41.	2.1	117
60	Connectivity and circuitry in a dish versus in a brain. Alzheimer's Research and Therapy, 2015, 7, 44.	3.0	11
61	Rodent models for Alzheimerâ€™s disease drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 703-711.	2.5	170
62	Increased neuronal PreP activity reduces AÎ² accumulation, attenuates neuroinflammation and improves mitochondrial and synaptic function in Alzheimer disease's mouse model. Human Molecular Genetics, 2015, 24, 5198-5210.	1.4	70
63	Characterization of a subpopulation of developing cortical interneurons from human iPSCs within serum-free embryoid bodies. American Journal of Physiology - Cell Physiology, 2015, 308, C209-C219.	2.1	17
64	SUMO modulation of protein aggregation and degradation. AIMS Molecular Science, 2015, 2, 382-410.	0.3	11
65	Characterization and Molecular Profiling of PSEN1 Familial Alzheimer's Disease iPSC-Derived Neural Progenitors. PLoS ONE, 2014, 9, e84547.	1.1	148
66	A Time Course Analysis of the Electrophysiological Properties of Neurons Differentiated from Human Induced Pluripotent Stem Cells (iPSCs). PLoS ONE, 2014, 9, e103418.	1.1	103
67	Alzheimer's Therapeutics Targeting Amyloid Beta 1â€“42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. PLoS ONE, 2014, 9, e111899.	1.1	151
68	Electrophysiological Profiles of Induced Neurons Converted Directly from Adult Human Fibroblasts Indicate Incomplete Neuronal Conversion. Cellular Reprogramming, 2014, 16, 439-446.	0.5	8
69	AÎ²1-42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy, 2014, 10, 1827-1843.	4.3	70
70	RAGE Inhibition in Microglia Prevents Ischemia-Dependent Synaptic Dysfunction in an Amyloid-Enriched Environment. Journal of Neuroscience, 2014, 34, 8749-8760.	1.7	47
71	Glut4 expression defines an insulin-sensitive hypothalamic neuronal population. Molecular Metabolism, 2014, 3, 452-459.	3.0	27
72	Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines. Biochemical Pharmacology, 2014, 88, 450-467.	2.0	151

#	Article	IF	Citations
73	Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits. Neuron, 2014, 83, 1131-1143.	3.8	863
74	A novel mechanism for cyclic adenosine monophosphateâ€“mediated memory formation: Role of amyloid beta. Annals of Neurology, 2014, 75, 602-607.	2.8	32
75	The schizophrenia susceptibility gene DTNBP1 modulates AMPAR synaptic transmission and plasticity in the hippocampus of juvenile DBA/2J mice. Molecular and Cellular Neurosciences, 2014, 58, 76-84.	1.0	18
76	Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiology of Aging, 2014, 35, 520-531.	1.5	75
77	Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease. Scientific Reports, 2014, 4, 7190.	1.6	84
78	Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits. Neuron, 2014, 83, 1482.	3.8	17
79	Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. Scientific Reports, 2014, 4, 6352.	1.6	41
80	Dynamin 1 Is Required for Memory Formation. PLoS ONE, 2014, 9, e91954.	1.1	32
81	Alzheimer's Therapeutics Targeting Amyloid Beta 1â€“42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits. PLoS ONE, 2014, 9, e111898.	1.1	120
82	Design, Synthesis, and Optimization of Novel Epoxide Incorporating Peptidomimetics as Selective Calpain Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 6054-6068.	2.9	27
83	Picomolar Amyloid-Î² Peptides Enhance Spontaneous Astrocyte Calcium Transients. Journal of Alzheimer's Disease, 2013, 38, 49-62.	1.2	59
84	SUMO and Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2013, 15, 720-736.	1.8	82
85	Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2013, 60, 285-294.	2.6	96
86	Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1). Mammalian Genome, 2013, 24, 30-43.	1.0	15
87	A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. Neurobiology of Aging, 2013, 34, 2052-2063.	1.5	104
88	Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nature Communications, 2013, 4, 1939.	5.8	84
89	Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS ONE, 2013, 8, e66226.	1.1	58
90	A Reliable Way to Detect Endogenous Murine Î²-Amyloid. PLoS ONE, 2013, 8, e55647.	1.1	32

#	Article	IF	Citations
91	An Intracellular Threonine of Amyloid-Î² Precursor Protein Mediates Synaptic Plasticity Deficits and Memory Loss. PLoS ONE, 2013, 8, e57120.	1.1	22
92	Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. Biochemical Journal, 2012, 446, 165-177.	1.7	89
93	5-HT4 Receptor Stimulation Leads to Soluble AÎ²PPÎ± Production Through MMP-9 Upregulation. Journal of Alzheimer's Disease, 2012, 32, 437-445.	1.2	18
94	Role of Leaky Neuronal Ryanodine Receptors in Stress- Induced Cognitive Dysfunction. Cell, 2012, 150, 1055-1067.	13.5	132
95	Amyloid-Î² Peptide: Dr. Jekyll or Mr. Hyde?. Journal of Alzheimer's Disease, 2012, 33, S111-S120.	1.2	91
96	Design and Synthesis of Neuroprotective Methylthiazoles and Modification as NO-Chimeras for Neurodegenerative Therapy. Journal of Medicinal Chemistry, 2012, 55, 6784-6801.	2.9	26
97	FoxO1 Target Gpr17 Activates AgRP Neurons to Regulate Food Intake. Cell, 2012, 149, 1314-1326.	13.5	164
98	Reduction of Synaptojanin 1 Ameliorates Synaptic and Behavioral Impairments in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 15271-15276.	1.7	69
99	Caspase-9 mediates synaptic plasticity and memory deficits of Danish dementia knock-in mice: caspase-9 inhibition provides therapeutic protection. Molecular Neurodegeneration, 2012, 7, 60.	4.4	19
100	Î²â€•but not Î³â€‘secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Molecular Medicine, 2012, 4, 171-179.	3.3	130
101	Synaptic underpinnings of altered hippocampal function in glutaminaseâ€deficient mice during maturation. Hippocampus, 2012, 22, 1027-1039.	0.9	19
102	Furoxans (1,2,5-Oxadiazole-N-Oxides) as Novel NO Mimetic Neuroprotective and Procognitive Agents. Journal of Medicinal Chemistry, 2012, 55, 3076-3087.	2.9	74
103	Inhibition of Amyloid-Î² (AÎ²) Peptide-Binding Alcohol Dehydrogenase-AÎ² Interaction Reduces AÎ² Accumulation and Improves Mitochondrial Function in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 2313-2320.	1.7	170
104	A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons. Experimental Neurology, 2011, 229, 409-420.	2.0	32
105	APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant. EMBO Journal, 2011, 30, 2501-2509.	3.5	49
106	Endogenous amyloidâ€Î² is necessary for hippocampal synaptic plasticity and memory. Annals of Neurology, 2011, 69, 819-830.	2.8	248
107	Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20822-20827.	3.3	62
108	Microglial Receptor for Advanced Glycation End Product-Dependent Signal Pathway Drives Î²-Amyloid-Induced Synaptic Depression and Long-Term Depression Impairment in Entorhinal Cortex. Journal of Neuroscience, 2010, 30, 11414-11425.	1.7	101

#	Article	IF	Citations
109	Memory Deficits Due to Familial British DementiaBRI2Mutation Are Caused by Loss ofBRI2Function Rather than Amyloidosis. Journal of Neuroscience, 2010, 30, 14915-14924.	1.7	52
110	Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits. Journal of Neuroscience, 2010, 30, 16419-16428.	1.7	155
111	The Ankyrin Repeat-rich Membrane Spanning (ARMS)/Kidins220 Scaffold Protein Is Regulated by Activity-dependent Calpain Proteolysis and Modulates Synaptic Plasticity. Journal of Biological Chemistry, 2010, 285, 40472-40478.	1.6	18
112	Preparation of Oligomeric β-amyloid₁₋₄₂ and Induction of Synaptic Plasticity Impairment on Hippocampal Slices. Journal of Visualized Experiments, 2010, , .	0.2	45
113	The ARMS/Kidins220 scaffold protein modulates synaptic transmission. Molecular and Cellular Neurosciences, 2010, 45, 92-100.	1.0	35
114	AÎ²-Dependent Inhibition of LTP in Different Intracortical Circuits of the Visual Cortex: The Role of RAGE. Journal of Alzheimer's Disease, 2009, 17, 59-68.	1.2	50
115	Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16877-16882.	3.3	220
116	Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-Â Load in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2009, 29, 8075-8086.	1.7	275
117	Glutaminase-Deficient Mice Display Hippocampal Hypoactivity, Insensitivity to Pro-Psychotic Drugs and Potentiated Latent Inhibition: Relevance to Schizophrenia. Neuropsychopharmacology, 2009, 34, 2305-2322.	2.8	76
118	Dysregulation of Histone Acetylation in the APP/PS1 Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 131-139.	1.2	255
119	A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. BMC Pharmacology, 2009, 9, S44.	0.4	1
120	Protection against Î²-amyloid induced abnormal synaptic function and cell death by Ginkgolide J. Neurobiology of Aging, 2009, 30, 257-265.	1.5	38
121	MAPK, Î²-amyloid and synaptic dysfunction: the role of RAGE. Expert Review of Neurotherapeutics, 2009, 9, 1635-1645.	1.4	60
122	Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration. Mini-Reviews in Medicinal Chemistry, 2009, 9, 448-462.	1.1	71
123	Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nature Medicine, 2008, 14, 1097-1105.	15.2	833
124	Oligomeric amyloid-Î² peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nature Neuroscience, 2008, 11, 547-554.	7.1	176
125	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiology of Disease, 2008, 31, 46-57.	2.1	92
126	Isolation and characterization of â€œReprotoxinâ€, a novel protein complex from Daboia russelii snake venom. Biochimie, 2008, 90, 1545-1559.	1.3	26

#	Article	IF	Citations
127	Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. Journal of Neurochemistry, 2008, 107, 1001-1013.	2.1	99
128	Picomolar Amyloid-Î² Positively Modulates Synaptic Plasticity and Memory in Hippocampus. Journal of Neuroscience, 2008, 28, 14537-14545.	1.7	627
129	Receptor for Advanced Glycation End Product-Dependent Activation of p38 Mitogen-Activated Protein Kinase Contributes to Amyloid-Î²-Mediated Cortical Synaptic Dysfunction. Journal of Neuroscience, 2008, 28, 3521-3530.	1.7	189
130	A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. Channels, 2008, 2, 230-232.	1.5	16
131	Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9415-9420.	3.3	157
132	A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 146-153.	1.3	214
133	Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and AÎ² accumulation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7327-7332.	3.3	230
134	Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatric Disease and Treatment, 2008, 4, 371.	1.0	80
135	Small Molecule, Non-Peptide p75NTR Ligands Inhibit AÎ²-Induced Neurodegeneration and Synaptic Impairment. PLoS ONE, 2008, 3, e3604.	1.1	112
136	Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 2008, 118, 2796-2807.	3.9	192
137	PIP2: a new key player in Alzheimer's disease. Cellscience, 2008, 5, 44-47.	0.3	11
138	RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease. Current Molecular Medicine, 2007, 7, 735-742.	0.6	151
139	Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons. Current Alzheimer Research, 2007, 4, 518-521.	0.7	27
140	A GluR1-cGKII Interaction Regulates AMPA Receptor Trafficking. Neuron, 2007, 56, 670-688.	3.8	166
141	?-Synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. European Journal of Neuroscience, 2007, 25, 3583-3596.	1.2	31
142	Neurotrophins, synaptic plasticity and dementia. Current Opinion in Neurobiology, 2007, 17, 325-330.	2.0	171
143	Learning and Memory and Synaptic Plasticity Are Impaired in a Mouse Model of Rett Syndrome. Journal of Neuroscience, 2006, 26, 319-327.	1.7	493
144	Ubiquitin Hydrolase Uch-L1 Rescues Î²-Amyloid-Induced Decreases in Synaptic Function and Contextual Memory. Cell, 2006, 126, 775-788.	13.5	385

#	Article	IF	Citations
145	Estimation of the Mean from Sums with Unknown Numbers of Summands. Biometrics, 2006, 62, 918-920.	0.8	3
146	BDNF-mediated neurotransmission relies upon a myosin VI motor complex. Nature Neuroscience, 2006, 9, 1009-1018.	7.1	132
147	Early presynaptic changes during plasticity in cultured hippocampal neurons. EMBO Journal, 2006, 25, 4361-4371.	3.5	19
148	Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation. Current Alzheimer Research, 2006, 3, 179-183.	0.7	22
149	Involvement of the Nitric Oxide Pathway in Synaptic Dysfunction Following Amyloid Elevation in Alzheimer's Disease. Reviews in the Neurosciences, 2006, 17, 497-523.	1.4	46
150	ABAD enhances AÎ²â€‰induced cell stress via mitochondrial dysfunction. FASEB Journal, 2005, 19, 1-25.	0.2	238
151	Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease. Current Alzheimer Research, 2005, 2, 137-140.	0.7	23
152	Amyloid-Â Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity. Journal of Neuroscience, 2005, 25, 6887-6897.	1.7	220
153	RAGE potentiates AÎ²-induced perturbation of neuronal function in transgenic mice. EMBO Journal, 2004, 23, 4096-4105.	3.5	311
154	Î±-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO Journal, 2004, 23, 4506-4516.	3.5	176
155	Cell Cultures From Animal Models of Alzheimer's Disease as a Tool for Faster Screening and Testing of Drug Efficacy. Journal of Molecular Neuroscience, 2004, 24, 015-022.	1.1	18
156	ABAD Directly Links AÂ to Mitochondrial Toxicity in Alzheimer's Disease. Science, 2004, 304, 448-452.	6.0	1,181
157	Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Annals of Neurology, 2004, 55, 801-814.	2.8	338
158	Calpain Mediates Calcium-Induced Activation of the Erk1,2 MAPK Pathway and Cytoskeletal Phosphorylation in Neurons. American Journal of Pathology, 2004, 165, 795-805.	1.9	125
159	Presynaptic CaMKII Is Necessary for Synaptic Plasticity in Cultured Hippocampal Neurons. Neuron, 2004, 42, 129-141.	3.8	113
160	Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. Journal of Clinical Investigation, 2004, 114, 1624-1634.	3.9	379
161	Calpain Inhibitors, a Treatment for Alzheimer's Disease: Position Paper. Journal of Molecular Neuroscience, 2003, 20, 357-362.	1.1	61
162	Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. Neurochemical Research, 2003, 28, 1009-1015.	1.6	16

#	Article	IF	Citations
163	Receptor protein tyrosine phosphatase Â is essential for hippocampal neuronal migration and long-term potentiation. EMBO Journal, 2003, 22, 4121-4131.	3.5	77
164	Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants. Science, 2003, 301, 805-809.	6.0	3,912
165	Amyloid Â-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13217-13221.	3.3	486
166	Calpain inhibitors. Journal of Molecular Neuroscience, 2002, 19, 135-141.	1.1	53
167	Presynaptic Role of cGMP-Dependent Protein Kinase during Long-Lasting Potentiation. Journal of Neuroscience, 2001, 21, 143-149.	1.7	162
168	Rapid Increase in Clusters of Presynaptic Proteins at Onset of Long-Lasting Potentiation. Science, 2001, 294, 1547-1550.	6.0	152
169	Chapter 11 Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Progress in Brain Research, 1998, 118, 155-172.	0.9	249
170	The Specific Role of cGMP in Hippocampal LTP. Learning and Memory, 1998, 5, 231-245.	0.5	112
171	Nitric Oxide Acts Directly in the Presynaptic Neuron to Produce Long-Term Potentiationin Cultured Hippocampal Neurons. Cell, 1996, 87, 1025-1035.	13.5	372
172	Fibrillatory activity and other membrane changes in partially denervated muscles. Muscle and Nerve, 1989, 12, 149-153.	1.0	14
173	Transitory l-carnitine depletion in rat skeletal muscle by d-carnitine. Pharmacological Research, 1989, 21, 163-168.	3.1	2